Low impact
A Mizuho healthcare analyst says an AstraZeneca-Bristol Myers merger worth $400 billion could reduce costs significantly if a specific condition is met.
Finnhub08/04, 12:17 AM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.